Company / Named in our posts
Kintara Therapeutics, Inc..
Follow Kintara Therapeutics, Inc.Clinical-stage immuno-oncology company developing novel personalized cancer vaccine product candidates designed to overcome primary resistance to immunotherapies like checkpoint inhibitors.[1]
01Deal
Deals on Carrywatch
Every deal that names Kintara Therapeutics, Inc., and its role in each.
Kintara Therapeutics, Inc. / TuHURA Biosciences, Inc.
Kintara Therapeutics and TuHURA Biosciences complete merger transaction
See deal detailsDeal Web
Kintara Therapeutics, Inc. and 1 firm it shares a posted deal with, and the path to any other firm.
News
Loading headlines.
Sources
As of 24 Oct 2026.
- 01Management’s Discussion and Analysis of Financial Condition and Results of Operations of TuHURA Biosciences, Inc.
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
- 02TuHURA Biosciences, Inc. Form 8-K/A (Amendment No. 1)
U.S. Securities and Exchange Commission · Researched 24 Oct 2026
Deal posts naming Kintara Therapeutics, Inc.:
- P01